TMRW Life Sciences, a NYC-based creator of the only FDA-cleared automated specimen management and storage platform for frozen human sperm, eggs and embryos, raised $28M in Series D funding.
The round was led by 5AM Ventures with participation from FIOS Venture Holdings, DF Investment Partners, Transformation Capital, Life Sciences Innovation Fund, and Casdin Capital. Additional support came from actress and advocate Amy Schumer, among others.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Louis Villalba, TMRW Life Sciences is a fertility technology company digitizing the IVF lab starting with automated platforms for the safe management and storage of frozen sperm, eggs and embryos. Frozen specimens can be digitally identified and tracked, safely managed with automated robotics, and remotely monitored around the clock. Its technology platforms set a new standard of care, reducing potential points of failure by 94% compared to manual systems.
